Damora Therapeutics, Inc. (DMRA)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $18.56
- As of
Kresmion compiles this page from DMRA's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Damora Therapeutics, Inc. (DMRA): 4 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 10-Q filed 2026-08-10.
See the full DMRA dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for DMRA on one page. Preview it with sample data, then open it live with a free account.
Preview the DMRA dossierActive signals for DMRA
- mediumEARNINGS_BEAT
Q2-2026: Beat consensus by 10.2%, EPS $-0.39 vs $-0.4342 estimate
- mediumNEW_POSITION
CITADEL ADVISORS LLC new position in DMRA
- highINSTITUTIONAL_EXIT
Point72 Asset Management, L.P. cut 96% of DMRA (2026Q2)
- highINSTITUTIONAL_EXIT
TWO SIGMA INVESTMENTS, LP cut 55% of DMRA (2026Q2)
- highCONSENSUS_BUY
3 tracked funds increased DMRA this 2026Q1 - institutional consensus
FREE, NO ACCOUNT
Every signal on DMRA, as it fires
You are seeing 5 of 13 signals recorded on DMRA since 2026-05-31.
The five above landed across 3 days. The other 8 were recorded on 2 other days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in DMRA (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| VIKING GLOBAL INVESTORS LPCUSIP 36322Q206 · 2026Q2 | $60.1M | 0.17% | , |
| CITADEL ADVISORS LLCCUSIP 36322Q206 · 2026Q2 | $4.3M | 0.00% | , |
| Point72 Asset Management, L.P.CUSIP 36322Q206 · 2026Q2 | $1.3M | 0.00% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 36322Q206 · 2026Q2 | $237K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, DMRA
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
DMRA against its peers
DMRA's return on equity of -87.3% ranks in the 22nd percentile of 15 Biotechnology sub-industry peers, fiscal periods ending between 2025-12-31 and 2026-03-31.
| Metric | DMRA | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | n/a | 170M | n/a | 8 |
| Operating margin | n/a | -85.3% | n/a | 9 |
| Net margin | n/a | -85.4% | n/a | 9 |
| Return on equity | -87.3% | -35.6% | 22 | 15 |
| 1 year | 45.6% | -8.2% | 75 | 13 |
Peers (18): DRTS, INBX, ORIC, TYRA, ANAB, NBTX, LBRX, VOR, REPL, GHRS, BCAX, TSHA, RAPP, SNDX, MAZE, JANX, IMCR, RARE. Left out: KARD (no annual filing), AAPG (period gap), TRAX (no annual filing), COAG (no annual filing), KALV (no annual filing), KLRA (no annual filing), AVLN (no annual filing). Fiscal periods ending between 2025-12-31 and 2026-03-31. Every figure is one full fiscal year read from one annual filing (DMRA: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow DMRA on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to DMRA for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.